Precision-driven. Patient-focused.
We’re transforming medicine by making early detection universal and accessible.
LEADING THE CHARGE FOR A BETTER TOMORROW.
We are the only biotech company developing the first screening test for early-stage stomach cancer, while actively closing the gap between early detection and accessible, timely treatment.
We bring innovation from the lab into the hands of doctors and patients, ensuring life-saving breakthroughs are never out of reach.
OUR MISSION IS CLEAR.
Pioneering to make the invisible visible – detecting cancer when it matters most.
OUR PURPOSE IS STRONG.
MEET GastroMDx™
EARLY DETECTION, MADE SIMPLE.
GastroMDx™ is a groundbreaking blood test designed to detect stomach cancer at its earliest stages — long before symptoms appear. With just a small blood sample, doctors can uncover what traditional methods often miss, giving patients a better chance at treatment and recovery. Our goal is to make early detection accessible, accurate, and effortless. Because when cancer is found early, lives are saved.
COLLABORATORS & INVESTORS
INSIGHTS THAT MOVE SCIENCE FORWARD.
Stay informed with The Ilico Journal; our collection of articles, research updates, and stories about innovation in early detection and diagnostics. Whether you’re a healthcare professional, patient, or simply curious about the future of cancer screening, our blog offers clear insights and real progress.
STAY IN TOUCH WITH US.
Sign up with your email address to receive news and updates.
